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Abstract
Background: Arsenic induces neural tube defects in several animal models, but its potential to cause neural tube
defects in humans is unknown. Our objective was to investigate the associations between maternal arsenic exposure,
periconceptional folic acid supplementation, and risk of posterior neural tube defect (myelomeningocele) among a
highly exposed population in rural Bangladesh.
Methods: We performed a case–control study that recruited physician-confirmed cases from community health clinics
served by Dhaka Community Hospital in Bangladesh, as well as local health facilities that treat children with
myelomeningocele. Controls were selected from pregnancy registries in the same areas. Maternal arsenic exposure was
estimated from drinking water samples taken from wells used during the first trimester of pregnancy. Periconceptional
folic acid use was ascertained by self-report, and maternal folate status was further assessed by plasma folate levels
measured at the time of the study visit.
Results: Fifty-seven cases of myelomeningocele were identified along with 55 controls. A significant interaction was
observed between drinking water inorganic arsenic and periconceptional folic acid use. As drinking water inorganic
arsenic concentrations increased from 1 to 25 μg/L, the estimated protective effect of folic acid use declined (OR 0.22
to 1.03), and was not protective at higher concentrations of arsenic. No main effect of arsenic exposure on
myelomeningocele risk was identified.
Conclusions: Our study found a significant interaction between drinking water inorganic arsenic concentration from
wells used during the first trimester of pregnancy and reported intake of periconceptional folic acid supplements.
Results suggest that environmental arsenic exposure reduces the effectiveness of folic acid supplementation in
preventing myelomeningocele.
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Background
Neural tube defects are debilitating birth defects charac-
terized by high rates of mortality and lifelong disabilities
in surviving children. Neural tube defects occur when
the neural plate fails to fold in the first 3 to 4 weeks of
gestation, causing death or permanent damage to the
spinal cord [1]. Neural tube defects are among the most
common birth defects worldwide, and their prevalence
varies from 5.3 per 10,000 live births in the United
States [2] to more than 10 per 1,000 pregnancies in
certain areas of China [3]. This variance likely reflects
differing contributions from risk factors such as preva-
lence of obesity and diabetes, nutritional status, usage of
folic acid supplementation and/or folic acid fortification
of the food supply, genetic susceptibility, and the presence
of environmental toxicants. Although studies have identi-
fied numerous risk factors, these account for less than
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half of all neural tube defects, suggesting that additional
genetic and environmental risk factors remain to be
identified [4].
Of particular concern is environmental exposure to
arsenic, which induces neural tube defects (exencephaly,
spina bifida occulta) in several animal models, including
mouse [5], rat [6], hamster [7], and chick [8]. Animal
studies have demonstrated that arsenic crosses the
placenta and preferentially accumulates in the neuroepi-
thelium of developing hamster, mouse, and monkey em-
bryos [9]. The potential mechanisms of arsenic-induced
neural tube defects include direct toxicity from reactive
oxygen species to the developing neural plate [8], and
disruption of maternal glucose metabolism [10]. In
addition, folate deficiency may exacerbate arsenic tox-
icity. Arsenic metabolism is catalyzed by enzymes that
require S-adenosylmethionine (SAM) as the methyl
donor. SAM is eventually regenerated via a process that
requires 5-methyltetrahydrofolate as a cofactor. Thus,
arsenic metabolism is dependent on the folate supply.
The associations between folate and arsenic toxicity have
been intensively studied in recent years. In mouse
models, mice with specific defects in folate transport
had higher rates of neural tube defects after in utero
arsenic exposure than wild-type mice similarly exposed
[5,11]. Understanding the associations between arsenic
and folate is particularly important for public health
practitioners as folic acid supplementation and fortifica-
tion is the primary strategy for neural tube defect preven-
tion. In addition to preventing neural tube defects, folic
acid is recognized to reduce the risk of other congenital
anomalies, with the strongest evidence supporting folic
acid’s role in reduction of cardiac malformations [12].
Exposure to arsenic through drinking water sources
from groundwater is a global public health emergency
that is particularly devastating in Bangladesh. According
to survey data from 2000 to 2010, an estimated 35 to 77
million people in the country have been chronically ex-
posed to arsenic in their drinking water in what has been
described as the largest mass poisoning in history [13].
The most recent survey of wells (2010) reported that 42%
of the water samples tested in Bangladesh had inorganic
arsenic levels exceeding the World Health Organization
drinking water guideline of 10 μg/L, and 27% had levels
that exceeded the Bangladesh guideline of 50 μg/L. Many
areas the inorganic arsenic concentrations in drinking
water exceeded 1000 μg/L [14].
This study aimed to identify whether environmental
arsenic exposure is associated with higher risk of neural
tube defects, and whether environmental arsenic expos-
ure modifies the protective effect of folic acid supple-
mentation. No data are available on the incidence and
prevalence of neural tube defects in Bangladesh due to
the country’s lack of a systematic surveillance system for
birth defects, although these malformations are fairly
common in clinical practices [15]. We therefore con-
ducted a case–control study that established a new case
ascertainment system. We administered a protocol that
measured inorganic arsenic concentrations in drinking
water from sources used during the first trimester of
pregnancy.
Methods
Study population
This case–control study was conducted between April
and November 2013 in the communities served by
Dhaka Community Hospital (DCH) in Bangladesh. The
unstable political situation in Bangladesh in November
2013 required the termination of the study after enrol-
ling 57 of the planned 60 cases and 55 of the planned 60
controls. DCH operates community health centers
throughout rural areas of Bangladesh, many of which are
located within regions that are high priorities for arsenic
remediation projects by the Bangladeshi government
and by nongovernmental organizations. The case ascer-
tainment system we established included regular com-
munication between DCH and district and union health
officials, health centers, and midwives in the Pabna,
Barisal, Rajshahi, Munshiganj, and Chittagong Districts,
as well as referral from local hospitals (Dhaka Commu-
nity Hospital, Bangladesh Medical College, Dhaka Shishu
Hospital, and Bangabandhu Sheikh Mujib Medical Uni-
versity). Eligible cases were infants and children under
age 1 year with myelomeningocele.Infants affected by
anterior neural tube defects (e.g. anencephaly) were not
included, as they were not expected to be reliably identi-
fied using our strategy. Most births in these areas occur
at home, and the birth of infants who die soon after de-
livery, as is expected for infants with anencephaly, is
often not reported.
To confirm case diagnoses, a pediatrician with expert-
ise in classifying neural tube defects (O.S.I.) performed a
physical examination or, if the subject was deceased,
reviewed photographs. Pregnancy registries from DCH-
affiliated health centers that were located in the same
areas as the cases served as the source of controls. Con-
trols were matched (1:1) by sex and age using the follow-
ing method: potential controls were separated into
groups corresponding to sex and birth quarter, and
placement on the list of potential controls was assigned
by random digit assignment. Once a case was enrolled,
potential controls were approached in order of assign-
ment on the list. Participation was 98% among potential
cases and 83% among potential controls. Reasons for re-
fusal to participate were similar between cases and con-
trols, including the lack of desire to participate in any
studies and the fear that giving blood will cause sickness.
Our a priori power estimate was that our pilot study
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sample size would provide 82% power if the true odds
ratio for myelomeningocele in infants exposed to high
levels of arsenic relative to low was 3.5. For this
estimate, we defined high-level arsenic exposure as levels
within the top quartile of observed; we assumed a
correlation coefficient between cases and controls of 0.2
and a Type I error of 0.05.
Informed consent was provided by parents before
enrollment. The Human Research Committees at Boston
Children’s Hospital (BCH) and at DCH approved this
study.
Questionnaires and medical history
Trained interviewers asked parents about their medical
histories, including the use of medications during preg-
nancy, family history, water consumption, and reproduct-
ive history. Periconceptional folic acid supplementation
was defined as reporting any intake of a folic acid-
containing supplement before within the two months
prior to awareness of the pregnancy. Nutritional intake of
mothers was assessed using a food frequency question-
naire previously validated in rural Bangladeshi populations
[16]. Children underwent a physical examination includ-
ing evaluation for level of neural tube defect and presence
of other congenital abnormalities.
Arsenic exposure from drinking water
At the time of enrollment, a water sample was collected
from the tube well each mother identified as her primary
source of drinking water at the time when she became
aware of her pregnancy. Water samples were collected
in 50 ml polypropylene tubes (BD Falcon, BD Bioscience,
Bedford, MA), preserved with Reagent Grade nitric acid
(Merck, Germany) to a pH < 2, and stored at room
temperature. Arsenic analysis was conducted by using
inductively coupled plasma mass-spectrometry (ICP-MS)
following US EPA method 200.8 (Spectrum Analytical,
Inc., Agawam, MA USA). For quality control, instrument
performance was validated by a spiked laboratory control
sample (ICP, Analytical Mixture 12 Solution A, High-
Purity Standards, Charleston, SC USA) with percent re-
coveries ranging from 98% to 107%. Of the 112 samples
included in this analysis, 45 (41.2%) had an inorganic ar-
senic concentration below the 0.15 μg/L limit of detection
(LOD). These samples were reassigned half the value of
the LOD for statistical analyses. Families found to have
drinking water inorganic arsenic concentrations ≥ 50 μg/L
(Bangladesh standard) were advised to seek alternative
drinking water.
Blood collection and processing
Maternal blood samples were collected via venipuncture
into two EDTA tubes and transported in an insulated
container to Dhaka within one day of collection, after
which they were stored at −20°C. Blood was centrifuged
and plasma collected into microcentrifuge tubes and
stored at −20°C. Blood/plasma samples were shipped to
HSPH on dry ice.
Folate analysis
Folate analyses were performed at the Vitamin Metabol-
ism Laboratory at the Jean Mayer USDA Human Nutri-
tion Research Center at Tufts University. We measured
total folate of the plasma samples by microbial assay
with the use of Lactobacillus casei [17]. We serially di-
luted 5 μL of each plasma sample and plated the samples
in triplicate onto a 96-microtiter well plate with 150 μL
of L. casei growth medium. We incubated the plates
overnight in a 37°C humid incubator and measured the
absorbance, which indicated microbial growth, with the
use of a 96-well plate reader (PowerWave HT; BioTek
Instruments Inc, Winooski, VT USA) at 595 nm. To test
if any arsenic in plasma affected the microbial assay, we
spiked 3 random samples with 5 ng/mL folic acid, and
there were no inhibitory components detected in the
plasma. The coefficients of variation for the assay using
one plasma sample with high folate concentration and
one sample with low folate concentration were 6.78%
and 4.73%, respectively.
Statistical analysis
Data were analyzed using SAS (version 9.3; SAS Institute,
Inc. Cary, NC USA). We used unconditional logistic re-
gression to calculate crude and adjusted odds ratios (ORs)
as well as 95% confidence intervals (CI). We did not use
conditional models because of the uneven numbers of
cases and controls, but instead forced the matching vari-
ables of child age and sex into all models, as strategy
suggested by Rothman and Greenland [18,19]. Data ex-
ploration suggested that the log-odds of case identification
varied exponentially with levels of inorganic arsenic in
well water. Consequently, log-transformed inorganic ar-
senic concentration was treated as a continuous variable
in regression models. Potential confounding factors for
the main effect of water arsenic included smoking status
of each parent, medication use, betel nut use, birth order,
folic acid use, family history of congenital defect, use of
pesticides during pregnancy, place of birth (home, birth
center, or hospital), and report of undergoing an ultra-
sound during pregnancy – the latter two variables were
considered additional measures of socioeconomic status.
We used inverse probability weighting (IPW) to cor-
rect locations that presented very different exposure pro-
files of our control populations, a method recently
reviewed succinctly by Seaman and White [20]. A large
percentage of our controls were drawn from Birhampur
Community Clinic (BCC) and Sirajdikhan Community
Clinic (SCC). BCC and SCC currently participate in
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other research activities conducted by our group; there-
fore, the population in those sites had a higher probabil-
ity of selection as a control. Using IPW, each individual
in the study population was given a sampling weight that
was the inverse of the probability of selection, in this
case the inverse of the proportion of controls from the
site from which the control was recruited. We investi-
gated effect modification with reported prenatal folic
acid supplementation by using interaction terms in our
weighted logistic regression models.
Results
The 57 cases of neural tube defects included 49 cases of
lumbar and 8 cases of cervical myelomeningocele. None
of the mothers reported alcohol consumption, smoking,
betel nut use, or use of medications other than pericon-
ceptional folic acid supplements (all mothers denied use
of anticonvulsant drugs) during pregnancy. None of the
mothers reported a diagnosis of diabetes, including ges-
tational diabetes. Overall, 39.4% of the study population
reported periconceptional folic acid use, which is similar
to other studies in Bangladesh [21]. As shown in Table 1,
mothers of controls were younger than mothers of cases
(23.1 years versus 25.2 years, p = 0.02). Mothers of con-
trols were more likely to report periconceptional folic
acid use than mothers of cases (71% versus 49%, p =
0.02). Plasma folate concentrations were higher at the
time of study visit among women who reported pericon-
ceptional folic acid use (Mean 12.7 nmol/L vs. 7.4 nmol/
L, p = 0.02). Plasma folate concentrations were not sig-
nificantly different between mothers of controls and
mothers of cases (Mean 10.6 nmol/L vs. 10.5 nmol/L,
p = 0.97).
Differences in median drinking water arsenic concen-
tration were observed. Controls had higher drinking
water inorganic arsenic concentrations, though this ap-
peared to be due to the contribution of controls from
one site only, Birhampur Community Clinic (BCC) in
Pabna (n = 22). Data exploration showed that controls
from sites aside from BCC had lower median water
arsenic concentrations than cases (Table 2).
In adjusted models, drinking water inorganic arsenic
concentration collected from wells that were used during
the first trimester of pregnancy was not significantly as-
sociated with risk of myelomeningocele. In models that
tested the interaction between water inorganic arsenic
concentrations and periconceptional folic acid use, how-
ever, the interaction was statistically significant (Table 3).
Using the parameters derived from our logistic regres-
sion model, the estimated OR for periconceptional folic
acid use demonstrates a decrease in the protective effect
of folic acid (OR = 0.22, 95% CI [0.13, 0.37] at 1 μg/L
drinking water inorganic arsenic; OR = 1.03, 95% CI
[0.55, 1.91]) at 25 μg/L drinking water inorganic arsenic)
(Figure 1).
Discussion
Our study found a significant interaction between drink-
ing water inorganic arsenic concentration from wells
used during the first trimester of pregnancy and re-
ported intake of perinatal folic acid supplements. As
drinking water inorganic arsenic concentrations in-
creased from 1 μg/L to 25 μg/L, the estimated protective
Table 1 Characteristics of cases of myelomeningocele and controls in Bangladesh (mean ± SD, except where noted)
Characteristic Controls (n = 55) Cases (n = 57) pValue
Age (months) 8.0 ± 4.9 5.9 ± 5.3 0.38
Male [n (%)] 32 (58) 34 (60) 0.87
Mother’s age at delivery (years) 23.1 ± 4.1 25.2 ± 5.4 0.02
Father’s age at delivery (years) 31.5 ± 5.4 32.5 ± 6.8 0.38
Reported prenatal folic acid use [n(%)] 39 (71) 28 (49) 0.02
First born 25 (46) 23 (40) 0.56
Cesarian section [n(%)] 24 (44) 23 (40) 0.72
Birth site 0.15
Hospital 23 (22) 14 (25)
Birth center/clinic 11 (20) 15 (26)
Home 24 (44) 28 (49)
Reported any ultrasound during pregnancy [n(%)] 50 (91) 48 (92) 0.19
Plasma folate concentration (nmol/L) 10.6 ± 14.7 10.5 ± 13.8 0.97
Level of neural tube defect
Lumbar [n (%)] 49 (86)
Cervical [n (%)] 8 (14)
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effect of folic acid use declined (OR = 0.22, 95% CI [0.13,
0.37] to OR = 1.03, 95% CI [0.55, 1.91]). This finding
suggests that environmental arsenic exposure reduces
the effectiveness of folic acid supplementation in pre-
venting neural tube defects.
Our study is the first in humans to demonstrate that
environmental arsenic exposure influences risk of myelo-
meningocele. At minimum, this study demonstrates that
there is a need for surveillance for neural tube defects
among populations with high environmental arsenic
exposure, and that additional preventive strategies may
be required in these areas. On a wider scale, the combin-
ation of folate deficiency and arsenic poisoning in
Bangladesh may be a setting for an unrecognized epi-
demic of neural tube defects.
Few studies have investigated the relationship between
arsenic exposure during pregnancy and risk of neural
tube defects in humans. Most recently, archeological
studies in an area of northern Chile characterized by
high environmental arsenic levels have shown that the
prevalence of spina bifida occulta among mummies was
13.5%, compared with 2.4% in a low-arsenic area
believed to have had no other differences in diet or
other factors [22]. Investigation of a cluster of anen-
cephalic births near the Texas-Mexico border found
that maternal and paternal exposures to arsenic were
associated with higher risk of neural tube defects, but
this finding was not statistically significant [23]. In
Bangladesh, a study of the pregnancy outcomes of
2006 women who regularly consumed drinking water
with high arsenic concentration found that there was a
small but statistically significant association (OR: 1.005,
95% CI: 1.000-1.010) between arsenic exposure and
congenital anomalies, though the study did not specify
the nature of these anomalies [24]. During an ecological
study in China’s Yangtze River Delta region, the arsenic
content of the soil in 40 towns and 80 villages was
associated with frequency of congenital anomalies, in-
cluding neural tube defects [25]. Critiques of the epi-
demiological literature have noted that human studies
of arsenic and neural tube defects have been limited by
lack of individual measures of exposure and by lack of
measures of exposure during the critical period of early
gestation [26].
Table 2 Distribution of water inorganic arsenic concentrations
Controls Controls
excluding BCC1
Cases
First trimester drinking water (μg/L)
n 55 33 54
Mean ± SD 49.4 ± 103.6 38.3 ± 101.6 19.8 ± 54.6
Median 6.9 <LOD2 0.7
25th percentile <LOD <LOD <LOD
75th percentile 54.9 8.5 12.7
Lowest <LOD <LOD <LOD
Highest 506.0 450.0 357.0
1BCC = Birhampur Community Clinic.
2LOD = limit of detection (0.15 μg/L).
Table 3 Results from weighted logistic regression models with the outcome neural tube defects (n = 112)
Variable Main effects model Interaction model
β OR (95% CI)1 pValue β OR (95% CI)1 pValue
Ln-water As 0.0278 1.03 (0.96, 1.11) 0.45 −0.3190 - -
Periconceptional folic acid use2 −1.2029 0.300 (0.19, 0.47) <0.0001 1.7280 - -
Home birth3 0.9224 2.51 (1.61, 3.92) <0.0001 1.0047 2.73 (1.72, 4.32) <0.0001
Mother’s age in years 0.1649 1.18 (1.10, 1.26) <0.0001 0.1573 1.17 (1.09, 1.26) <0.0001
Father’s age in years −0.0607 0.94 (0.89, 1.00) 0.05 −0.0416 0.96 (0.90, 1.01) 0.17
Child sex4 0.9152 2.50 (1.56, 3.99) 0.0001 0.7986 2.22 (1.38, 3.59) 0.001
Child age in months −0.1305 0.88 (0.84, 0.92) <0.0001 −0.1337 0.88 (0.94, 0.91) <0.0001
Ln-water As*prenatal folic acid use 0.4636 - <0.0001
1OR indicates odds of being a CASE.
2Reported use = 1, No reported use = 0.
3Home birth = 1, Clinic or Hospital birth = 0.
4Male = 1, Female = 0.
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The strengths of our study include the use of individ-
ual measures of exposure, including measurements of
the drinking water from wells that mothers identified as
their source of water at the time they became aware of
their pregnancy—a time point that is very close to the
crucial time point in neural tube defect pathogenesis.
Our interviews with community members indicated a
frequent practice for women to return to their parents’
homes in the months around childbirth, therefore we
were careful to identify the exact well used during the
first trimester. Though the drinking water was collected
from the identified wells approximately one year after
the onset of pregnancy, arsenic concentrations have been
shown to be stable over a one year time period, with the
most recent study in Araihazar, Bangladesh, demonstrat-
ing variability of 10% to 30% in well samples collected
every 2 to 4 weeks over a period of 3 years [27]. In our
study, drinking water inorganic arsenic concentration
was used as a proxy for in utero arsenic concentration,
and drinking water arsenic concnetration may not accur-
ately reflect the internal arsenic dose encountered by the
developing embyro. Previous studies in humans support
placental transfer of arsenic; studies of pregnant women
in Argentina and Bangladesh have shown that the
arsenic concentration in cord blood is similar to that in
maternal blood [28,29].
Another reason our study may have found associations
is that the arsenic concentrations in our study were
much higher than those observed in other studies. For
example, among controls in the 2006 cluster case–
control study conducted along the Texas/Mexico border,
less than 2% of women were found to have inorganic ar-
senic concentrations greater than 10 μg/L in drinking
water [23], whereas in this study the drinking water in-
organic arsenic concentration was greater than 10 μg/L
in 55.5% of controls, and the maximum drinking water
arsenic concentration (506 μg/L) was over 50 times that
threshold.
An additional strength of our study is that we mini-
mized the potential recall bias by validating folic acid
use reports with biomarkers. This comparison has con-
siderable limitations, as we were only able to measure
plasma folate after pregnancy. Ours is the first study in
Bangladesh to measure plasma folate concentrations
among mothers of children with neural tube defects,
and we can infer from the strong correlation between
the two measures that women who reported periconcep-
tional folic acid use have more access to folate contain-
ing foods and/or folic acid supplements. Nevertheless,
the potential for recall bias is inherent in all retrospect-
ive studies and is an important limitation of this study.
Folate is the centerpiece of the one-carbon metabolism
pathway that has a key role in reactions that are important
in many key biological processes including synthesis of
DNA, and for the generation of methyl groups used in a
multitude of important reactions. Arsenic is metabolized
in humans through sequential addition of methyl groups
acquired from the one-carbon metabolism pathway. In tri-
als, folic acid supplementation has been shown to reduce
total blood arsenic concentrations by increasing the
methylation of inorganic arsenic into less toxic species
[30]. One possible explanation for the observed interaction
Figure 1 The predicted odds ratio of periconceptional folic acid use and myelomeningocele from the interaction model at various
distributions of inorganic arsenic concentration in drinking water. Average (mean) values of parental age, child age, child sex and home
birth were used to estimate odds ratios.
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between arsenic and folic acid supplementation is that
arsenic depletes the supply of methyl donors necessary for
reactions important in normal neural tube development.
Arsenic may also increase the risk for neural tube de-
fects by disruption of maternal glucose homeostasis. Two
well-established risk factors for neural tube defects are
maternal gestational diabetes and prepregnancy obesity
[31-36]. Accumulating evidence has shown an increase
risk of type 2 diabetes in general populations exposed to
arsenic [37-39], and there is growing evidence that preg-
nant women also experience increase risk of dysregulated
glucose homeostasis with arsenic exposure [40]. Although
the mechanisms underlying the risks of gestational dia-
betes remain unclear, there is evidence from experimental
models that in utero hyperglycemia can cause excess gen-
eration of reactive oxygen species due to mitochondrial
dysfunction [41] and activation of programmed cell death
(apoptotic) signaling cascades [42]. None of the women in
our study reported a diagnosis of gestational diabetes,
but subclinical alterations in glucose regulation due to
arsenic toxicity are likely to be present, and may play a
role in modulating risk of neural tube defects.
Though the interaction between water arsenic concen-
tration and reported folic acid use was highly significant,
our study did not demonstrate a significant primary (or
main) effect of drinking water arsenic concentrations on
myelomeningocele risk. This is most likely because our
pilot study was underpowered, though it is also possible
that even higher arsenic exposures are needed to dem-
onstrate a primary effect. Another potential explanation
is that our study was designed to identify myelomenin-
gocele at the time of birth or presentation to medical
care; a surveillance system following all pregnancies
might have identified a more severe phenotype. Infants
with arsenic-induced neural tube defects may have died
during gestation, or were otherwise undiscovered. An-
other possible explanation for why we did not find a
main effect of arsenic exposure comes from the multi-
factorial threshold model of neural tube defects that
posits that neural tube defects result from an additive
contribution of several risk factors, which are each indi-
vidually insufficient to disrupt neural tube closure [43].
Despite our attempts to adjust for confounding and
selection bias, residual differences between the study
groups and study sites are still possible, and thus, more
detailed collection of important covariates including so-
cioeconomic status, nutritional intake and folate status
is needed in future studies.
Our findings raise important questions about the risk
of neural tube defects in arsenic-endemic areas and
the effectiveness of folic acid supplements. Larger,
prospective studies with more refined measures of
folic acid supplementation and folate status of mothers
are needed.
Conclusions
Environmental arsenic exposure may reduce the protect-
ive effects of folic acid supplementation in high exposure
areas, such as Bangladesh. More surveillance for neural
tube defects is needed in arsenic endemic areas. Add-
itional preventive measures, such as higher doses of
folic acid, as well as early detection and management of
maternal diabetes, may be needed in areas with high
levels of environmental arsenic exposure.
Abbreviations
DCH: Dhaka community hospital; LOD: Limit of detection; IPW: Inverse
probability weighting; BCC: Birhampur community clinic; SCC: Sirajdikhan
community clinic.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
MM, OSI, RH, FS, QQ and DCC designed research. MM, OSI, LP, JS, EGR, SM,
MGM, QQ and MR conducted research. MM, LV and DCC performed
statistical analyses. MM, LP, LV and DCC wrote the paper. MM had primary
responsibility for final content. All authors read and approved the final
manuscript.
Acknowledgements
Funding for this study was provided by the Child Neurology Foundation and
the Harvard School of Public Health NIEHS Center (ES000002). Dr. Mazumdar
was supported by a Mentored Career Development Award from the NIEHS,
National Institutes of Health (K23 ES017437). Additional support was
provided by NIEHS grant P42 ES16454.
We thank the study staff at Dhaka Community Hospital including Biplop
Biswas and Md Sohel Rana, who conducted field visits. Li Su supervised
laboratory work at HSPH. We thank the Boston Children’s Hospital Clinical
Research Center (CRC) for their assistance. Kimberly Chin from the CRC
prepared and managed the REDCap database. Senior statisticians Al Ozonoff
and Kush Kapur prepared randomization protocols for participation selection.
Shaye Moore and Elizabeth Jarvis provided editorial assistance.
Author details
1Department of Neurology, Boston Children’s Hospital, 300 Longwood
Avenue, Boston, MA, USA. 2Department of Environmental Health, Harvard
School of Public Health, 665 Huntington Avenue, Boston, MA, USA. 3Dhaka
Community Hospital, 190/1 Baro Moghbazar, Wireless Railgate, Dhaka 1217,
Bangladesh. 4Bangladesh Medical College, 14/A Dhanmondi, Dhaka 1209,
Bangladesh. 5Department of Biostatistics, Harvard School of Public Health,
655 Huntington Avenue, Boston, MA, USA. 6Jean Mayer USDA Human
Nutrition Research Center on Aging, Tufts University, 711 Washington Street,
Boston, MA, USA.
Received: 5 January 2015 Accepted: 20 March 2015
References
1. Volpe JJ. Neurology of the newborn. 5th ed. Philadelphia: Saunders/Elsevier;
2008.
2. Williams J, Mai CT, Mulinare J, Isenburg J, Flood TJ, Ethen M, et al. Updated
estimates of neural tube defects prevented by mandatory folic Acid
fortification - United States, 1995–2011. MMWR Morb Mortal Wkly Rep.
2015;64(1):1–5.
3. Li Z, Ren A, Zhang L, Ye R, Li S, Zheng J, et al. Extremely high prevalence of
neural tube defects in a 4-county area in Shanxi Province, China. Birth
Defects Res A Clin Mol Teratol. 2006;76(4):237–40.
4. Agopian AJ, Tinker SC, Lupo PJ, Canfield MA, Mitchell LE. National birth
defects prevention S: proportion of neural tube defects attributable to
known risk factors. Birth Defects Res A Clin Mol Teratol. 2013;97(1):42–6.
5. Hill DS, Wlodarczyk BJ, Finnell RH. Reproductive consequences of oral
arsenate exposure during pregnancy in a mouse model. Birth Defects Res B
Dev Reprod Toxicol. 2008;83(1):40–7.
Mazumdar et al. Environmental Health  (2015) 14:34 Page 7 of 8
6. Beaudoin AR. Teratogenicity of sodium arsenate in rats. Teratology.
1974;10(2):153–7.
7. Carpenter SJ. Developmental analysis of cephalic axial dysraphic disorders in
arsenic-treated hamster embryos. Anat Embryol. 1987;176(3):345–65.
8. Han ZJ, Song G, Cui Y, Xia HF, Ma X. Oxidative stress is implicated in
arsenic-induced neural tube defects in chick embryos. Int J Dev Neurosci.
2011;29(7):673–80.
9. Hanlon DP, Ferm VH. Placental permeability of arsenate ion during early
embryogenesis in the hamster. Experientia. 1977;33(9):1221–2.
10. Hill DS, Wlodarczyk BJ, Mitchell LE, Finnell RH. Arsenate-induced maternal
glucose intolerance and neural tube defects in a mouse model. Toxicol
Appl Pharmacol. 2009;239(1):29–36.
11. Wlodarczyk BJ, Zhu H, Finnell RH. Mthfr gene ablation enhances susceptibility
to arsenic prenatal toxicity. Toxicol Appl Pharmacol. 2014;275(1):22–7.
12. Feng Y, Wang S, Chen R, Tong X, Wu Z, Mo X. Maternal folic Acid
supplementation and the risk of congenital heart defects in offspring:
a meta-analysis of epidemiological observational studies. Sci Rep.
2015;5:8506.
13. Smith AH, Lingas EO, Rahman M. Contamination of drinking-water by
arsenic in Bangladesh: a public health emergency. Bull World Health Organ.
2000;78(9):1093–103.
14. Chakraborti D, Rahman MM, Das B, Murrill M, Dey S, Chandra Mukherjee S,
et al. Status of groundwater arsenic contamination in Bangladesh: a 14-year
study report. Water Res. 2010;44(19):5789–802.
15. Dey AC, Shahidullah M, Mannan MA, Noor MK, Saha L, Rahman SA. Maternal
and neonatal serum zinc level and its relationship with neural tube defects.
J Health Popul Nutr. 2010;28(4):343–50.
16. Chen Y, Ahsan H, Parvez F, Howe GR. Validity of a food-frequency questionnaire
for a large prospective cohort study in Bangladesh. Br J Nutr. 2004;92(5):851–9.
17. Horne DW, Patterson D. Lactobacillus casei microbiological assay of folic
acid derivatives in 96-well microtiter plates. Clin Chem. 1988;34(11):2357–9.
18. Rothman KJ, Greenland S. Matching. In: Rothman KJ, Greenland S, editors.
Modern Epidemiology. 2nd ed. New York: Lippincott, Williams & Wilkins;
1998. p. 147–61.
19. Rothman KJ, Greenland S. Introduction to Regression Modelling. In:
Rothman KJ, Greenland S, editors. Modern Epidemiology. 2nd ed. New York:
Lippincott, Williams & Wilkins; 1998. p. 401–34.
20. Seaman SR, White IR. Review of inverse probability weighting for dealing
with missing data. Stat Methods Med Res. 2013;22(3):278–95.
21. Baqui AH, El-Arifeen S, Darmstadt GL, Ahmed S, Williams EK, Seraji HR, et al.
Effect of community-based newborn-care intervention package implemented
through two service-delivery strategies in Sylhet district, Bangladesh: a cluster-
randomised controlled trial. Lancet. 2008;371(9628):1936–44.
22. Silva-Pinto V, Arriaza B, Standen V. [Spina bifida occulta associated with
environmental arsenic exposure in a prehispanic sample from northern
Chile]. Rev Med Chil. 2010;138(4):461–9.
23. Brender JD, Suarez L, Felkner M, Gilani Z, Stinchcomb D, Moody K, et al.
Maternal exposure to arsenic, cadmium, lead, and mercury and neural tube
defects in offspring. Environ Res. 2006;101(1):132–9.
24. Kwok RK, Kaufmann RB, Jakariya M. Arsenic in drinking-water and reproductive
health outcomes: a study of participants in the Bangladesh Integrated Nutrition
Programme. J Health Popul Nutr. 2006;24(2):190–205.
25. Wu J, Chen G, Liao Y, Song X, Pei L, Wang J, et al. Arsenic levels in the soil
and risk of birth defects: a population-based case–control study using GIS
technology. J Environ Health. 2011;74(4):20–5.
26. DeSesso JM. Teratogen update: inorganic arsenic. Teratology. 2001;64(3):170–3.
27. Dhar RK, Zheng Y, Stute M, van Geen A, Cheng Z, Shanewaz M, et al.
Temporal variability of groundwater chemistry in shallow and deep aquifers
of Araihazar, Bangladesh. J Contam Hydrol. 2008;99(1–4):97–111.
28. Concha G, Vogler G, Nermell B, Vahter M. Low-level arsenic excretion in
breast milk of native Andean women exposed to high levels of arsenic in
the drinking water. Int Arch Occup Environ Health. 1998;71(1):42–6.
29. Hall M, Gamble M, Slavkovich V, Liu X, Levy D, Cheng Z, et al. Determinants
of arsenic metabolism: blood arsenic metabolites, plasma folate, cobalamin,
and homocysteine concentrations in maternal-newborn pairs. Environ
Health Perspect. 2007;115(10):1503–9.
30. Gamble MV, Liu X, Slavkovich V, Pilsner JR, Ilievski V, Factor-Litvak P, et al.
Folic acid supplementation lowers blood arsenic. Am J Clin Nutr. 2007;86
(4):1202–9.
31. Shaw GM, Todoroff K, Finnell RH, Lammer EJ. Spina bifida phenotypes in
infants or fetuses of obese mothers. Teratology. 2000;61(5):376–81.
32. Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal
obesity and risk for birth defects. Pediatrics. 2003;111(5 Pt 2):1152–8.
33. Soler NG, Walsh CH, Malins JM. Congenital malformations in infants of
diabetic mothers. Q J Med. 1976;45(178):303–13.
34. Waller DK, Shaw GM, Rasmussen SA, Hobbs CA, Canfield MA, Siega-Riz AM,
et al. Prepregnancy obesity as a risk factor for structural birth defects. Arch
Pediatr Adolesc Med. 2007;161(8):745–50.
35. Hendricks KA, Nuno OM, Suarez L, Larsen R. Effects of hyperinsulinemia and
obesity on risk of neural tube defects among Mexican Americans.
Epidemiology. 2001;12(6):630–5.
36. Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation
to risk of neural tube defects. JAMA. 1996;275(14):1089–92.
37. Pan WC, Seow WJ, Kile ML, Hoffman EB, Quamruzzaman Q, Rahman M,
et al. Association of low to moderate levels of arsenic exposure with risk of
type 2 diabetes in Bangladesh. Am J Epidemiol. 2013;178(10):1563–70.
38. Kuo CC, Moon K, Thayer KA, Navas-Acien A. Environmental chemicals and
type 2 diabetes: an updated systematic review of the epidemiologic
evidence. Curr Diab Rep. 2013;13(6):831–49.
39. Maull EA, Ahsan H, Edwards J, Longnecker MP, Navas-Acien A, Pi J, et al.
Evaluation of the association between arsenic and diabetes: a national
toxicology program workshop review. Environ Health Perspect. 2012;120
(12):1658–70.
40. Ettinger AS, Zota AR, Amarasiriwardena CJ, Hopkins MR, Schwartz J, Hu H,
et al. Maternal arsenic exposure and impaired glucose tolerance during
pregnancy. Environ Health Perspect. 2009;117(7):1059–64.
41. Zangen SW, Yaffe P, Shechtman S, Zangen DH, Ornoy A. The role of
reactive oxygen species in diabetes-induced anomalies in embryos of
Cohen diabetic rats. Int J Exp Diabetes Res. 2002;3(4):247–55.
42. Yang P, Li X, Xu C, Eckert RL, Reece EA, Zielke HR, et al. Maternal
hyperglycemia activates an ASK1-FoxO3a-caspase 8 pathway that leads to
embryonic neural tube defects. Science signaling. 2013;6(290):ra74.
43. Harris MJ, Juriloff DM. Mouse mutants with neural tube closure defects and
their role in understanding human neural tube defects. Birth Defects Res A
Clin Mol Teratol. 2007;79(3):187–210.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mazumdar et al. Environmental Health  (2015) 14:34 Page 8 of 8
